MHLW Approves Entyvio, Imfinzi, Lynparza Breast Cancer Use, and More

July 3, 2018
Japan’s health ministry approved a throng of new medicines on July 2, with Takeda Pharmaceutical earning the OK for its Entyvio (vedolizumab) ulcerative colitis (UC) drug, and AstraZeneca notching two big wins with its cancer drugs Imfinzi (durvalumab) and Lynparza...read more